Gainers

• Liminatus Pharma (NASDAQ:LIMN) shares rose 36.9% to $1.47 during Wednesday's regular session. The company's market cap stands at $28.9 million.
• InnovAge Holding (NASDAQ:INNV) stock increased by 35.15% to $7.65. The company's market cap stands at $767.9 million. As per the news, the Q2 earnings report came out yesterday.
• Bristol-Myers Squibb Company Celegne Contingent Value Rights (NYSE:CELGR) shares moved upwards by 16.91% to $0.09.
• ENvue Medical (NASDAQ:FEED) stock rose 16.66% to $2.87. The market value of their outstanding shares is at $2.6 million.
• Vyome Holdings (NASDAQ:HIND) shares rose 15.94% to $2.4. The market value of their outstanding shares is at $11.6 million.
• DarioHealth (NASDAQ:DRIO) stock moved upwards by 12.45% to $12.37. The company's market cap stands at $74.3 million.

Losers

• NewGenIvf Group (NASDAQ:NIVF) stock fell 27.3% to $0.93 during Wednesday's regular session. The company's market cap stands at $1.2 million.
• Azenta (NASDAQ:AZTA) shares fell 24.13% to $28.0. The company's market cap stands at $1.6 billion. As per the news, the Q1 earnings report came out today.
• BGM Group (NASDAQ:BGM) stock decreased by 21.77% to $1.87. The market value of their outstanding shares is at $479.4 million.
• bioAffinity Technologies (NASDAQ:BIAF) shares decreased by 17.76% to $0.88. The market value of their outstanding shares is at $4.8 million.
• China Pharma Holding (AMEX:CPHI) shares fell 17.71% to $0.75. The market value of their outstanding shares is at $4.5 million.
• CDT Equity (NASDAQ:CDT) stock decreased by 15.79% to $1.12. The market value of their outstanding shares is at $3.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.